Effects of a single introduction of pamidronate on intact bone under the conditions of the experimental model of the treatment of tuberculosis ostitis
- 作者: Petukhova V.1, Mushkin A.1,2, Kostik M.3, Vinogradova T.1
-
隶属关系:
- St. Petersburg Research Institute of Phthisiopulmonology
- Academician Pavlov First St. Petersburg State Medical University
- St. Petersburg State Pediatric Medical University
- 期: 卷 13, 编号 6 (2022)
- 页面: 55-62
- 栏目: Original studies
- URL: https://journals.rcsi.science/pediatr/article/view/133041
- DOI: https://doi.org/10.17816/PED13655-62
- ID: 133041
如何引用文章
详细
BACKGROUND: Information about the features of intact bone tissue of the contralateral segment in the treatment of tuberculous osteitis is absent in the literature.
AIM: Study of the features of intact bone tissue in the conditions of complex treatment of experimental tuberculous osteitis.
MATERIALS AND METHODS: On an experimental model of tuberculous osteitis of the condyle of the right femur (Mycobacterium tuberculosis H37Rv) in 21 rabbits, the morphometric characteristics of the contralateral femurs, representatively selected from 4 groups, were studied: group (control) — who did not receive either surgical or medical treatment; groups 2–4 — radical surgical removal of the focus, supplemented: No. 2 — antituberculosis therapy, group 3 — antituberculosis therapy and a single injection of bisphosphonates (pamidronate), group 4 — a single injection of bisphosphonates. In autopsy material studied: the area of bone tissue, the thickness of bone beams, the number of osteoblasts, osteocytes, osteoclasts and the proportion of their active forms.
RESULTS: The following features were revealed in intact samples of different groups: group 1 — the minimum area of bone tissue and the thickness of the beams, the maximum number of osteoblasts, including active ones, the average number of osteocytes; groups 2 and 3 — average values of the area and thickness of bone beams, the average number of osteoblasts, the pool of osteocytes is represented mainly by inactive cells; groups 3 and 4 the minimum value of active osteoblasts; group 4 — the maximum thickness of the bone beams, a greater total number of osteoblasts and osteocytes. No osteoclasts were found in any group.
CONCLUSIONS: Different ratios of bone tissue area, thickness of bone beams, and osteoforming cellular elements in animals receiving different treatment indicate both the systemic effect of a specific process and the drug effect of anti-tuberculosis drugs and bisphosphonates on uninfected bones.
作者简介
Veronika Petukhova
St. Petersburg Research Institute of Phthisiopulmonology
Email: nika_add@mail.ru
ORCID iD: 0000-0002-2358-5529
Postgraduate Student
俄罗斯联邦, Saint PetersburgAlexander Mushkin
St. Petersburg Research Institute of Phthisiopulmonology; Academician Pavlov First St. Petersburg State Medical University
Email: aymushkin@mail.ru
ORCID iD: 0000-0002-1342-3278
MD, PhD, Dr Med Sci, Professor, Chief Researcher; Professor of the Department of Traumatology and Orthopedics
俄罗斯联邦, Saint Petersburg; Saint PetersburgMikhail Kostik
St. Petersburg State Pediatric Medical University
Email: kostmikhail@yandex.ru
ORCID iD: 0000-0002-1180-8086
MD, PhD, Dr Med Sci, Professor of the Department of Hospital Pediatrics
俄罗斯联邦, Saint PetersburgTatiana Vinogradova
St. Petersburg Research Institute of Phthisiopulmonology
编辑信件的主要联系方式.
Email: vinogradova@spbniif.ru
ORCID iD: 0000-0002-5234-349X
MD, PhD, Dr Med Sci, Professor, Chief Researcher, coordinator of the direction “Experimental tuberculosis and innovative technologies”
俄罗斯联邦, Saint Petersburg参考
- Alatortsev AV, Kirillova ES, Mushkin AYu, Ryasnyanskaya TB. Prognozirovanie ortopedicheskikh posledstvii operirovannykh tuberkuleznykh ostitov u detei. Problemy Tuberkuleza i Boleznei Legkikh. 2006; (12):58–61. (In Russ.)
- Zinchenko YuS, Basancova NYu, Starshinova AYa, et al. Tuberculosis today: the main trends of research on prevention, diagnosis and treatment. Russian Biomedical Research. 2018;3(4):24–34. (In Russ.)
- Kenis VM, Sapogovskiy AV, Prokopenko TN, et al. bone mineral density in children with cerebral palsy and spina bifida treated with ibandronate. Pediatric Traumatology, Orthopaedics and Reconstructive Surgery. 2020;8(2):129–136. (In Russ.) doi: 10.17816/PTORS33961
- Kosulin AV, Elyakin DV. Donor site morbidity as a problem of spinal surgery: systematic review. Diseases of the donor zone as a problem of surgical vertebrology: a systematic review. Spine Surgery. 2016;13(2):45–51. (In Russ.) doi: 10.14531/ss2016.2.45-51
- Lozovskaya ME, Zakharova OP, Udaltsova EN. Tuberkulez u podrostkov v sovremennykh usloviyakh. Medicine: Theory and Practice. 2019;4(5):319–320. (In Russ.)
- Mitrofanov VN, Zhivtsov OP, Orlinskaya NYu, et al. Technology for repairing osteomyelitic bone defects using autologous mesenchymal stromal cells on a collagen matrix in experiment. Modern Technologies in Medicine. 2021;13(1):42 (In Russ.) doi: 10.17691/stm2021.13.1.05
- Mushkin AYu, Vishnevskii AA. Clinical recommendations for the diagnosis of infectious spondylitis (draft for discussion). Medical Alliance. 2018;(3):64–74. (In Russ.)
- Mushkin AYu, Pershin AA, Sovetova NA. Bone and joint tuberculosis in children: algorithms for diagnosis and principles for treatment. Medical Alliance. 2015;(4):36–45. (In Russ.)
- Andreasen CM, Jurik AG, Glerup MB, et al. Response to early-onset pamidronate treatment in chronic nonbacterial osteomyelitis: a retrospective single-center study. The Journal of Rheumatology. 2019;46(11): 1515–1523. doi: 10.3899/jrheum.181254
- Antoniazzi F, Mottes M, Fraschini P, et al. Osteogenesis imperfecta: practical treatment guidelines. Paediatr Drugs. 2000;2(6):465–488. doi: 10.2165/00128072-200002060-00005
- Boyce AM, Kelly MH, Brillante BA, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab. 2014;99(11):4133–4140. doi: 10.1210/jc.2014-1371
- Careri S, Vitiello R, Oliva MS, et al. Masquelet technique and osteomyelitis: innovations and literature review. Eur Rev Med Pharmacol Sci. 2019;23(2 Suppl): 210–216. doi: 10.26355/eurrev_201904_17495
- Cornelis F, Truchetet ME, Amoretti N, et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy. Bone. 2014;58:11–16. doi: 10.1016/j.bone.2013.10.004
- Dudareva M, Hotchen AJ, Ferguson J, et al. The microbiology of chronic osteomyelitis: Changes over ten years. Journal of Infection. 2019;79(3):189–198. doi: 10.1016/j.jinf.2019.07.006
- Hogan JI, Hurtado RM, Nelson SB. Mycobacterial musculoskeletal infections. Infectious Disease Clinics of North America. 2017;31(2):369–382. doi: 10.1016/j.idc.2017.01.007
- Kim MJ, Kim SN, Lee IS, et al. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. Journal of Pediatric Endocrinology and Metabolism. 2015;28(11–12):1343–1350. doi: 10.1515/jpem-2014-0527
- Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation. 2002;110(9): 1293–1299. doi: 10.1172/JCI15952
- Sułko J, Ebisz M, Bień S, et al. Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children. Joint Bone Spine. 2019;86(6):783–788. doi: 10.1016/j.jbspin.2019.06.005